LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

Kodu・Aktsiate loetelu・Gossamer Bio Inc

Gossamer Bio Inc

Suletud

SektorTervishoid

3.77 4.43

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.52

Max

3.85

Põhinäitajad
By Trading Economics
Sissetulek	-9.9M -48M
Müük	1.8M 13M
Aktsiakasum	-0.21
Kasumimarginaal	-362.728
Töötajad	144
EBITDA	-10M -45M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+196.83% upside

Turustatistika
By TradingEconomics
Turukapital	242M 789M
Eelmine avamishind	-0.66
Eelmine sulgemishind	3.77

Uudiste sentiment

By Acuity

70%

30%

338 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

1.06 / 1.23 Toetus ja vastupanu

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. dets 2025, 17:39 UTC

Suurimad hinnamuutused turgudel

Vanda Pharmaceuticals Rises on FDA Biologics License Application

15. dets 2025, 23:44 UTC

Market Talk

Gold Steady Ahead of U.S. Employment Report -- Market Talk

15. dets 2025, 23:38 UTC

Market Talk

Global Equities Roundup: Market Talk

15. dets 2025, 23:38 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Decline -- Market Talk

15. dets 2025, 22:19 UTC

Market Talk

Clean-Energy Project Developers Benefit From 'Deep Buyer Universe' -- Market Talk

15. dets 2025, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

15. dets 2025, 21:42 UTC

Omandamised, ülevõtmised, äriostud

Comcast Spinoff Versant Debuts at Modest Valuation, a Signal for a Warner Bros. Sale -- Barrons.com

15. dets 2025, 21:32 UTC

Omandamised, ülevõtmised, äriostud

Comcast Spinoff Versant Debuts at Modest Valuation, Puts Warner Bros. Discovery in Focus -- Barrons.com

15. dets 2025, 21:28 UTC

Omandamised, ülevõtmised, äriostud

iRobot Files for Bankruptcy After Amazon Was Forced to Scrap Its Deal to Buy the Roomba Maker -- Barrons.com

15. dets 2025, 21:26 UTC

Omandamised, ülevõtmised, äriostud

Commercial Metals Completes Acquisition of Foley Products for $1.84B >CMC

15. dets 2025, 21:23 UTC

Omandamised, ülevõtmised, äriostud

Perseus Mining: Reserves Right to Make Further Proposal If Circumstances Change

15. dets 2025, 21:23 UTC

Omandamised, ülevõtmised, äriostud

Perseus Mining: Does Not Intend to Submit Revised Takeover Proposal For Predictive

15. dets 2025, 21:23 UTC

Omandamised, ülevõtmised, äriostud

Perseus Mining: Notes Predictive Shares Trade at Discount to Value Implied By Perseus Proposal

15. dets 2025, 21:22 UTC

Omandamised, ülevõtmised, äriostud

Perseus Mining: Believes Revised Robex Merger Inferior to Its Own Takeover Proposal

15. dets 2025, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Commercial Metals Completes Acquisition Of Foley Products Company >CMC

15. dets 2025, 21:15 UTC

Omandamised, ülevõtmised, äriostud

ServiceNow Completes Acquisition Of Moveworks >NOW

15. dets 2025, 21:00 UTC

Omandamised, ülevõtmised, äriostud

Comcast Spinoff Versant Debuts at Low Valuation; Could Figure in Warner Bros. Discovery Takeover Battle -- Barrons.com

15. dets 2025, 20:57 UTC

Omandamised, ülevõtmised, äriostud

Comcast Spinoff Versant Debuts at Low Valuation; Could Figure in Warner Bros. Discovery Takeover Battle -- Barrons.com

15. dets 2025, 20:36 UTC

Market Talk

Oil Futures Fall Further on Oversupply Concerns -- Market Talk

15. dets 2025, 20:31 UTC

Market Talk

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

15. dets 2025, 20:27 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

ServiceNow's Acquisition Streak Could Cause Investor Angst -- Market Talk

15. dets 2025, 20:15 UTC

Market Talk

El Buen Fin Helps Lift Mexican November Retail Sales -- Market Talk

15. dets 2025, 19:22 UTC

Market Talk

Gold and Silver Gain to Start Week -- Market Talk

15. dets 2025, 18:37 UTC

Market Talk

Oil Futures Extend Losses On Oversupply Worries -- Market Talk

15. dets 2025, 18:29 UTC

Market Talk

ServiceNow Seen Facing Pressure if Government Budgets Decline -- Market Talk

15. dets 2025, 17:58 UTC

Market Talk

Canada Housing Market In Search Of a Bottom -- Market Talk

15. dets 2025, 17:36 UTC

Market Talk

Canada Data Signal Underlying Price Pressures Persist -- Market Talk

15. dets 2025, 17:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. dets 2025, 17:36 UTC

Tulu

Texas Instruments Stock Slips. It Caught a Rare Downgrade From Goldman Sachs. -- Barrons.com

15. dets 2025, 17:30 UTC

Omandamised, ülevõtmised, äriostud

Cinemark Stock Could Fall Even More If Netflix Buys Warner Bros., Analyst Says -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

196.83% tõus

12 kuu keskmine prognoos

Keskmine 11.25 USD 196.83%

Kõrge 15 USD

Madal 8 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Gossamer Bio Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.06 / 1.23Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

338 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.